Kornimate/medical-research-clean huggingface dataset:
antagonist activation measurement at the ankle using high-density and bipolar surface emg in chronic hemiparesis

Conditions: Stroke; Muscle Hypertonia; Spasticity, Muscle

Summary: in chronic hemiparesis, abnormal antagonist muscle activation in the paretic lower limb contributes to impair ambulation capacities. a biased estimate of antagonist muscle activation when using surface bipolar emg compared with high-density (hd) emg has been previously reported in healthy subjects. the present study compares muscles cocontraction at the paretic ankle estimated with a pair of and multi-channel surface emg.

in chronic hemiparesis, gait velocity deficit is associated with a disturbed voluntary movement caused especially by inappropriate antagonist muscle activation. the present study investigates muscles cocontraction at the paretic ankle estimated with a pair of and multi-channel surface emg (hd-emg) in patients after stroke. hd-emgs were collected from gastrocnemius medialis (gm), tibialis anterior (ta) and soleus (so) during isometric contractions. from these emgs the study asked whether bipolar and hd-emgs provided comparable estimates of antagonist activation. two active contraction levels (submaximal vs. maximal) and knee positions (flexed vs. extended) were assessed for each muscle. notwithstanding the evidence of localized antagonist activation in the gm muscle of healthy subjects, hypothesizing equally localized antagonist activation in the paretic limb may not follow from the current literature. in virtue of evidence supporting the enlargement of motor unit territories in paretic and hyperactive muscles, it may be that stroke survivors have lost their ability to regionally and appropriately activate their muscle. in this case, bipolar and hd-emg would be expected to provide comparable antagonist activation coefficients.

Eligibility criteria:
inclusion criteria: * hemiparesis due to a non-evolutive central nervous system lesion * time since lesion ≥ 6 months * ability to walk 10 meters barefoot without any assistance * cognitive abilities to understand the verbal instructions for the test according to the investigator's judgment * absence of botulinum toxin injections within the last 3 months prior to enrolment exclusion criteria: * botulinum toxin injections within the last 3 months prior to enrolment
live smart: smartphone intervention for weight control

Conditions: Overweight; Obesity

Summary: the purpose of this study is to compare three methods of delivering behavioral weight loss treatment.participants are randomly assigned to one of three 18-month weight loss treatments (group, individual, or smartphone treatment). participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months. participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. they will also attend one-on-one sessions with a weight loss counselor every month for 18 months. assessment visits are conducted at baseline, 6, 12, and 18 months.


Eligibility criteria:
inclusion criteria: * body mass index (kg/m2) of 25-45. * english language fluency * ability to read at a 6th grade level * availability to attend weekly treatment sessions in providence, ri exclusion criteria: * any heart condition that limits ability to participate in physical activity * chest pain * any cognitive of physical limitation that would preclude use of a smartphone * serious mental illness * historical or current eating disorder * previous or planned bariatric surgery * use of weight loss medication * recent pregnancy or a plan to become pregnant in the next 6 months * participation in a study at the weight control and diabetes research center within the last two years * a weight loss of greater than 5% body weight in the last 6 months

Keywords: overweight obesity weight loss
change feasibility study

Conditions: Hearing Loss

Summary: the purpose of the feasibility study is to examine audiological outcomes (audiometry and speech perception) and safety (adverse events and adverse device effects) with the nucleus ci532 cochlear implant in group of adult subjects (n=12) who meet current criteria for cochlear implantation.


Eligibility criteria:
inclusion criteria: 1. meet current cochlear implant indications at the implanting centre 2. in addition to meeting current cochlear implant indications, subjects must also possess preoperative unaided hearing thresholds between 40 to 65 db hl at 250 \& 500hz in the ear to be implanted. 3. fluent speaker in the local language used to assess clinical performance 4. eighteen years of age or older at the time of implantation with no upper age limit exclusion criteria: 1. evidence of hearing loss prior to 5 years of age. 2. sensorineural severe-to-profound hearing loss greater than 20 years at 2 khz and above. 3. simultaneous bilateral cochlear implantation or prior cochlear implantation in the ear to be implanted. 4. additional disabilities that may affect the subject's participation or safety during the clinical investigation. 5. medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery. 6. ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination. 7. hearing impairment due to lesion or neuropathy of the acoustic nerve, viii nerve or central auditory pathway. 8. active middle-ear infection, 9. tympanic membrane perforation 10. unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices 11. unwillingness or inability of the candidate to comply with all investigational requirements. 12. patients with existing csf shunts or drains, existing perilymph fistula, skull fracture or csf leak. 13. patients with recurrent episodes of bacterial meningitis.

Keywords: cochlear prosthesis implantation
clinical and biochemical features for the identification of dominant calpainopathies

Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A

Summary: mutations in the capn3 gene cause muscular dystrophies with dysfunction in calpain-3. calpainopathies are usually inherited in an autosomal recessive manner but in some families they can occur in a dominant inheritance. the significance of heterozygous variants is difficult to interpret in the absence of family history. in this study, the investigators will review the clinical and laboratory information in a cohort of patients identified in the participating centers, with the aim of improving the diagnostic strategy of dominant calpainopathies.

the investigators will review clinical and biomarker information in a cohort of 50 patients with heterozygous variants in the capn3 gene. patients are referred by participating centers who will provide anonymised information on the clinical phenotype and laboratory test results. suitable subjects will be contacted to obtain informed consent. pseudonymised anamnestic data will be collected from the patient's clinical history and medical records.the aim is to identify a set of multidisciplinary data sufficient to define a diagnostic algorithm for the dominant calpainopathies.

Eligibility criteria:
inclusion criteria: * clinical lgmd phenotype, family history with dominant inheritance or sporadic cases, single variant in capn3, second variant excluded by mlpa (multiplex ligation probe amplification) or by analysis of mrna extracted from muscle. exclusion criteria: * no variants in capn3, two variants in capn3
chinese nutritional risk screening and intervention registration study in geriatric patients

Conditions: Malnutrition; Old Age

Summary: this study is a multi-center observational study, led by the department of geriatrics, peking union medical college hospital, with 99 tertiary hospitals as sub-centers. patients in the geriatrics department from september 2020 to september 2021 are consecutively enrolled .basic information and nutritional risk assessment is registered and the outcome within 90 days after hospitalization will be recorded.daily energy, protein and fiber are 75% of the target amount as the standard for feeding.

this study is a multi-center observational study.patients in the geriatrics department from september 2020 to september 2021 are consecutively enrolled .the patients' basic information, nutritional assessment, diet and blood biochemical indicators after hospitalization will be registered.the status of nutritional treatment and rehabilitation training and whether there is any adverse outcome when discharged from the hospital will be recorded. daily energy, protein and fiber are 75% of the target amount as the standard for feeding.the diet, exercise status and adverse outcomes of participants within 90 days after hospitalization will be followed up through outpatient, telephone or remote consultation.primary endpoint-the impact of nutritional therapy (energy, protein, dietary fiber compliance or failure) on mortality, new infections, falls and readmissions in elderly hospitalized patients within 90 days after hospitalization; secondary endpoints-the change of the nutrition indicators, the physical function and quality of life of the participants within 90 days after hospitalization.

Eligibility criteria:
inclusion criteria: * patients aged ≥65 years old in geriatrics; * expected hospitalization ≥4 days; * patients with nrs 2002≥3 points; * sign informed notice. exclusion criteria: * end-stage patients (estimated survival time ≤ 3 months); * transfer to other departments during hospitalization; * contraindications to nutritional therapy (such as hemodynamic instability); * have participated in other nutritional research projects.

Keywords: malnutrition older adults adverse outcomes nutrition intervention
peripheral oxygen saturation (spo2) directed oxygen therapy

Conditions: Critical Illness

Summary: investigators hypothesized that a relative low spo2 directed oxygen therapy would reduced the mortality in patients staying longer than 72 hours in icus.

in fear of harmful effect of hypoxia, oxygen therapy is commonly used, especially in critically ill patients in intensive care units (icus). however, hyperoxia can be harmful too. examples are myocardial infarction (mi) patients and patients resuscitated to return of spontaneous circulation after cardiac arrest. in air versus oxygen in myocardial infarction (avoid) trial, meyhoff and colleagues proved hyperoxia caused more cardiac injury in patients with st-elevation mi but without hypoxia. kilgannon and colleagues found that arterial hyperoxia following resuscitation from cardiac arrest were associated with increased in-hospital mortality, and a pulse oxygen saturation (spo2) of 94-98% was recommended. recently, panwar and colleagues found that compared to liberal oxygen strategy (spo2 ≥96%), conservative oxygen strategy (spo2 of 88%-92%) was feasible in patients receiving invasive mechanical ventilation. girardis and colleagues found control oxygen therapy (targeting spo2 of 94%-98% or pao2 of 70-100mmhg) resulted lower icu mortality than conventional oxygen therapy (spo2 ≥97%) in the randomized clinical trial called oxygen-icu. however, the oxygen-icu trial was single-centered, early-terminated with only 480 patients included and led to an unplanned interim analysis. in this larger multicenter trial, investigators hypothesized that a relative low spo2 directed oxygen therapy was safe and would reduced the 28-day mortality in patients staying longer than 72 hours in icus.

Eligibility criteria:
inclusion criteria: * aged 18 years or older and admitted into icu, with expected stay in icu more than 72 hours or longer. exclusion criteria: * under 18 years old, expected stay in icu less than 72 hours, unconsented inclusion, icu readmission, patients with acute exacerbation of chronic obstruction disease, patients with severe acute respiratory distress syndrome (defined as pao2/fio2 ≤ 100mmhg and peep ≥10cmh2o), decision to withhold life-sustaining treatment, physician forgetting to screen during 12 hours after admission, pregnancy, patients with acute myocardial infarction, paraquat poisoning and patients on extracorporeal membrane oxygenation (ecmo) or planned to be on ecmo.
smartphone application for university students with binge drinking behavior

Conditions: Alcohol Drinking; Binge Drinking

Summary: alcohol use is a causal factor in more than 200 diseases and injury conditions (see icd-10) and in france, alcohol is the first cause of hospitalization. binge drinking (bd) has emerged as a major public health issue among student populations and is associated with negative consequences and social, cognitive and brain alterations. more than half of french university students have reported bd in the past month and are at increased risk of several alcohol-related consequences such as memory and sleep impairments, and reduced quality of life. bd is also a major risk factor in the development of alcohol addiction, with individual and environmental factors playing a role that is still poorly understood. moreover, most students and young adults are reluctant to seek interventions when it is provided by health care professionals (only 4-5%) and have poor insight with regard to their alcohol use patterns / habits. thus, there is an urgent need for developing effective prevention and intervention programs to reduce alcohol drinking in students. recent studies have demonstrated that new types of technology-delivered interventions are promising tools for addressing unhealthy alcohol use. for example, an uncontrolled trial pilot study using a smartphone application-delivered intervention produced a reduction in both number of drinks per week and bd from baseline to 3-month follow-up. a recent review also showed significant outcomes of a mobile health intervention for self-control of unhealthy alcohol use. the investigators hypothesize that a timeline follow-back and personalized feedback based on the use of a mobile application can reduce excessive alcohol intake at 3-months. this study will provide scientific knowledge about bd in students, but also regarding a new type of intervention that could be effective for prevention in non-treatment seeking individuals and reducing the severity of health problems associated with excessive alcohol intake.


Eligibility criteria:
inclusion criteria: * students between 18 and 25 years old * auq score greater than or equal to 24, and audit score greater than or equal to 3 for its first 3 items. drinking details with the ddq when necessary. * bd behavior: at least one occasion with 6 or more drinks in the last 3 months. * consent to be included in the study * affiliated to social security exclusion criteria: * not having a smartphone with an apple or android system. * previous use of the mydéfi smartphone application * declaration of a psychiatric / neurologic condition * pregnant, parturient or breastfeeding woman * subject under guardianship, curators or restricted under public law

Keywords: alcohol binge drinking phosphatidylethanol smartphone health
antiplaque, antigingivitis and anti-inflammatory effects of myrrh mouthwash

Conditions: Gingivitis; Dental Plaque

Summary: myrrh-based mouthwash has the potential to be a suitable alternative to the gold standard chlorhexidine mouthwash for dental plaque and gingivitis reduction. to date, however, little research has been carried out to determine its true clinical significance on periodontal health. the purpose of this study is to evaluate and compare the efficacy of 1% myrrh mouthwash with commercially available 0.2% chlorhexidine mouthwash in terms of plaque and gingivitis reduction and inflammatory mediator (interleukin-1β) inhibition.

this will be a single-center, triple-blinded, randomized, three-arm parallel, controlled trial in periodontally healthy adult volunteers (no clinical attachment loss and bleeding on probing \< 10%). we will include all eligible patients seeking dental treatment at the center after gaining a written informed consent. after the initial dental screening and a session of professional teeth cleaning procedures, participants will be instructed to refrain from regular oral hygiene practices for 2 weeks to develop experimental gingivitis. participants will then be randomly allocated to one of the three treatment groups \[1:1:1\] using a simple randomization method (i.e. computer-generated random numbers). they will be instructed to continue refrain from regular oral hygiene practices and use 10 ml of the assigned mouthwash twice daily for 1 minute. treatment effect will be evaluated by comparing the baseline (day 0) and post-intervention (day 14) values of all clinical parameters (modified gingival index, plaque index, proinflammatory interleukin-1β biomarker, and gingival bleeding index).

Eligibility criteria:
inclusion criteria: * good periodontal health; * dentition of ≥20 teeth and a minimum of 5 teeth per quadrant; * the absence of any systemic illness; * no history of oral prophylaxis in the past 6 months; * no relevant medical history that might compromise normal oral hygiene practice. exclusion criteria: * pocket depth \>3 mm * severe misalignment of teeth; * the presence of orthodontic appliances; * intake of antibiotic and/or anti-inflammatory medications within the past 6 months; * use of tobacco; * inability of comply with the study's appointment schedule; * pregnant or breast-feeding mothers.

Keywords: gingivitis herbal myrrh myrrha antigingivitis antiplaque il-1 dental plaque
effects of ribavirin on zidovudine or stavudine

Conditions: HIV Infections; Hepatitis C

Summary: the purpose of this study is to see how treatment of hepatitis c (hcv) patients with ribavirin (rbv) affects the anti-hiv drugs stavudine (d4t) or zidovudine (zdv). studies have shown that rbv may interfere with the action of zdv and d4t. there is little information about the way these drugs interact in the body. this study will examine how the drug rbv affects levels of zdv or d4t in patients who are currently on stable anti-hiv therapy.

rbv, a nucleoside analogue, is used for the treatment of hepatitis c virus (hcv) in alliance with interferon-alfa 2a/2b in patients with hiv-1. the mechanism of action of rbv has led to in vitro studies examining the agonism/antagonism in efficacy occurring when used in combination with nucleoside reverse transcriptase inhibitors (nrtis). the primary objective of the pharmacology component of this current study will be the evaluation of the effect of rbv on the intracellular activation of zdv or d4t owing to the reported antagonism observed in vitro. pharmacokinetic (pk) evaluations for plasma zdv or d4t and intracellular zdv or d4t and measurements of their triphosphate anabolites are performed before initial rbv dosing (within 2 weeks of visit) and 8 weeks after rbv administration. thymidine triphosphate (ttp) concentrations also are quantitated to permit estimation of the ratio of active drug to endogenous triphosphate concentrations. for entry, prior to rbv dosing, blood samples are collected within 2 hours prior to the zdv or d4t dose and then at hours 1, 4, and 8 post dosing. following the entry pk blood draws, patients initiate rbv treatment within 2 weeks of the first pk study day. for the week 8 evaluation (measured as 8 weeks following initiation of rbv), blood samples are collected prior to the zdv or d4t dose and then at hours 1, 4, and 8 post dosing.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are at least 13 years of age. * have written consent from parent or guardian if under 18 years of age. * have hiv infection. * have been receiving zdv or d4t for at least 4 weeks prior to study entry. * are planning to receive rbv-containing hepatitis treatment through their doctor or through coenrollment in another actg protocol within 2 weeks following entry into the study. * have not received rbv for at least 6 months prior to study entry if they were previously treated with rbv. * weigh more than 110 pounds (50 kg). exclusion criteria patients will not be eligible for this study if they: * are pregnant. * use rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 14 days of study entry. * abuse alcohol or drugs. patients in methadone programs may participate.

Keywords: ribavirin drug interactions drug therapy, combination zidovudine stavudine reverse transcriptase inhibitors anti-hiv agents pharmacokinetics area under curve
study to examine the safety and efficacy of pimavanserin for the treatment of agitation and aggression in alzheimer's disease (serene)

Conditions: Agitation and Aggression in Alzheimer's Disease

Summary: to evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment


Eligibility criteria:
inclusion criteria: 1. male or female, 50 years of age or older 2. can understand the nature of the trial and protocol requirements and provide signed informed consent * from patient, if deemed competent to provide consent * from an appropriate person (e.g. patient's legally authorized representative (lar) with the patient's assent) if patient is deemed not competent to provide informed consent. 3. has a diagnosis of probable ad according to the national institute on aging-alzheimer's association (nia-aa) guidelines 4. meets criteria for agitation according to the international psychogeriatric association (ipa) guidelines 5. lives at home or in an assisted living or care facility (but has the capacity to visit the clinic as an outpatient). subjects must have been at their current location for at least 3 weeks prior to screening and plan to remain at the same location for the duration of the trial. 6. has a designated study partner/caregiver who is in contact with the patient at least 3 times a week on 3 separate days 7. female patients must be of non-childbearing potential or must agree to use an acceptable method of contraception or abstinence , for at least 1 month prior to randomization, during the study, and 1 month following completion of the study 8. the patient and caregiver are willing and able to participate in all schedule evaluations and complete all required tests exclusion criteria: 1. the agitation/aggression is attributable to concomitant medications, environmental conditions, substance abuse, or active medical or psychiatric condition 2. patient is receiving skilled nursing care for any medical condition other than dementia 3. treatment with an antipsychotic medication within 2 weeks of baseline visit or 5 half lives, whichever is longer 4. patient or study partner/caregiver has a medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments. 5. has had a myocardial infarction within the last six months 6. has a history or symptoms of long qt syndrome 7. has a history of a significant psychotic disorder before or during the diagnosis of probable alzheimer's disease (including, but not limited to schizophrenia or bipolar disorder) 8. patient is bedridden or has any significant medical condition that is unstable and would place the patient at undue risk from study drug or study procedures 9. has a sensitivity to pimavanserin or its excipients 10. has previously participated in a clinical study with pimavanserin 11. has a global clinician assessment of suicidality (gcas) score of 3 or 4 based on investigator's assessment of behavior within the last 3 months at screening or since last visit at baseline